Research programme: TNF inhibitors - e-TherapeuticsAlternative Names: ETS3100
Latest Information Update: 10 Jul 2015
At a glance
- Originator e-Therapeutics
- Class Small molecules
- Mechanism of Action Tumour necrosis factor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammation
Most Recent Events
- 11 Jun 2015 Preclinical trials in Inflammation in United Kingdom (unspecified route)